UC San Diego researchers improve accuracy of breast cancer prognosesOctober 16, 2007One of the many unknowns facing women who are diagnosed with breast cancer is predicting the likelihood that the cancer will spread to other parts of the body - metastasize. Researchers from UC San Diego are looking to change that. UCSD bioengineering professor Trey Ideker is pioneering a more accurate approach for predicting the risk of breast cancer metastasis in individual patients. This work will be published online by the journal Molecular Systems Biology on Tuesday 16 October. Distant metastases are the main cause of death among breast cancer patients, but physicians have a hard time predicting if a patient's breast cancer is likely to spread. The researchers from UCSD and the Korea Advanced Institute of Science and Technology took advantage of new protein interaction databases and identified networks of genes from breast cancer patients - rather than individual genes - that can be used to predict whether a breast cancer tumor is likely to spread. Their results offer new mechanistic insights into breast cancer metastasis and are more accurate and reproducible than two sets of individual marker genes currently used to help predict the likelihood that a patient's breast cancer will spread. "Over the years, large numbers of women have endured unnecessarily harsh treatments, such as aggressive chemotherapy, due to our inability to predict metastasis risks with high accuracy. One of our goals is to improve this situation," said Trey Ideker, a bioengineering professor from the UCSD Jacobs School of Engineering and the senior author of the new study. "The next step is to confirm these results in other clinical trials. It will be absolutely crucial to confirm our findings on other patient data before we think too hard about bringing this technology to the clinic," Ideker said. The new research may also help researchers discover disease-causing genes and more precisely classify and diagnose cancer and other diseases. "Our work supports the notion that cancer is a disease of pathways," said Ideker. "The keys for understanding at least some of these pathways are encoded in protein networks." The new study uses the same gene expression data used in two well-known studies: Vijver et al. in Nature and Wang et al. in the Lancet. Each study yielded a set of about 70 single-gene markers that are now used in hospitals to help predict the likelihood of breast cancer metastasis. "We saw about a 9 percent increase in metastasis prediction accuracy over the two main sets of individual gene markers," said Ideker, who explained that his team raised metastatic prediction accuracy for breast cancer to roughly 72 percent. "But there is still plenty of room for improvement," he said. "The big difference between our work and the work outlined in Vijver and Wang is that we painted the existing gene expression data onto newly available maps of protein interactions," said Ideker. Some refer to these maps as "wiring diagrams." By focusing on how the proteins within cells interact, the researchers were able to look at the aggregate behavior of genes that are connected in functional networks. This approach improved their ability to predict which tumors would spread. Using a mathematical approach for the prediction of metastasis (involving both machine learning and dimensionality reduction), the researchers calculated the average behavior of subnetworks of proteins and used this information to uncover subnetworks that predict metastasis better than individual gene markers. The team uncovered 149 discriminative subnetworks consisting of 618 genes from the patients from the van de Vijver et al. data set and 243 discriminative subnetworks with 906 genes from the Wang et al. data set. Each subnetwork is suggestive of a distinct functional pathway or complex, yielding many known and novel pathway hypotheses in organisms for which sufficient protein interaction data have been measured, the authors write in their Molecular Systems Biology paper. For example, the researchers show that a well-known breast cancer susceptibility gene, P53, plays a central role in several protein subnetworks; it interconnects many expression-responsive genes (genes that show up as potential markers in expression-only analyses). Interestingly, P53 itself does not show up as "significant" in conventional expression clustering or classification methods. "A key feature of our approach is the ability to identify crucial genes that fly under the radar of conventional gene expression analyses," said Ideker. The phenotypic changes most indicative of breast cancer metastasis need not be regulated at the level of expression, the authors write. The researchers also show that their subnetwork markers are significantly more reproducible between data sets than individual marker genes selected without network information. University of California - San Diego |
|||||||||||||||||||||
| Related Breast Cancer Current Events and Breast Cancer News Articles Menopause-cardiology consensus statement on cardiovascular disease and on HRT A menopause-cardiology consensus statement has called for direct action to prevent cardiovascular disease (CVD) in menopausal women. The statement also concludes that there is little evidence of increased CVD risk in taking HRT. Researchers Identify Role of Gene in Tumor Development, Growth and Progression Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. UCLA researchers create 'fly paper' to capture circulating cancer cells Just as fly paper captures insects, an innovative new device with nano-sized features developed by researchers at UCLA is able to grab cancer cells in the blood that have broken off from a tumor. Fertility procedures need not delay breast cancer treatment for younger women A new study published in the November issue of the Journal of the American College of Surgeons shows that breast cancer patients under 40 years old who undergo fertility preservation do not face a significant delay in the treatment of their disease when their care is coordinated in a timely fashion. Coffee break: Compound brewing new research in colon, breast cancer A compound in coffee has been found to be estrogenic in studies by Texas AgriLife Research scientists. Drugs to treat anemia in cancer patients linked to thromboembolism Medications frequently given to cancer patients to reduce their risk of anemia are associated with an increased risk of deep vein thrombosis or pulmonary embolism, according to new research led by Dawn Hershman, M.D, M.S., co-director of the breast cancer program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian Hospital/Columbia University Medical Center. Discovery in worms by Queen's researchers points to more targeted cancer treatment Researchers at Queen's University have found a link between two genes involved in cancer formation in humans, by examining the genes in worms. The groundbreaking discovery provides a foundation for how tumor-forming genes interact, and may offer a drug target for cancer treatment. FDA approved leukemia drugs shows promise in ovarian cancer cells The drug Sprycel, approved for use by the U.S. Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a study by researchers with UCLA's Jonsson Comprehensive Cancer Center found. Carnegie Mellon researchers link health-care debate to risk of dying in US and Europe The current health care debate in the United States is complicated. Trade-offs between heath care expenditures, lifestyle choices and life expectancy have been suggested but seldom clearly demonstrated. Scientists uncover new key to the puzzle of hormone therapy and breast cancer The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer. More Breast Cancer Current Events and Breast Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||